The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Fugazi1: you are on full throttle and keep your funds ready, I mean virtual funds and it may reach 142 P much sooner than you think.
I am not surprised BB. The stock has had good run since from middle of Sept from 137 P around to 190P. You should not fall in love with stock and try to make some profit and move on or cut your losses ?
sundezena: you are absolutely correct because Fugazi! has a wild dream and he is dreaming all the time!
Fugazi1: Keep your funds ready because you have been dreaming for 142 P for a while!
Agreed iparsnip: although patents are first steps and they don’t have any significance until the final product is manufactured but this is very very long shot. Unless very large pharmaceutical company involves Nuvec will be stuck to research desks
You are right Mozart: let us hope sooner or later any large Pharma gets on board to develop and implement Nuvec sooner than later because other ideas may take over the market
Agreed Mr Triumph, I think Nuvec is good concept but it is very long shot and unless any large Pharma becomes partner to speed up the process to its product development and delivery ,Nuvec will be sitting idle up to patent approvals and research extent and other companies will take the market by developing their ideas and products .
No idea, if it is fantastic news for N4P
BBC News:
An experimental drug for severe Covid cuts the risk of hospitalisation or death by about half, interim clinical trial results suggest.
The tablet - molnupiravir - was given twice a day to patients recently diagnosed with the disease.
US drug-maker Merck said its results were so positive that outside monitors had asked to stop the trial early.
It said it would apply for emergency use authorisation for the drug in the US in the next two weeks.
Confirmed: Sussex-based IosBio has found a way to turn injected vaccines into tablets and signed a deal with California's ImmunityBio. N4 Pharma better speed up the process to find a partner at least in Europe to speedy development leading to trials.
Patents are beginning and we have to wait for any partner to comes along to implement Nuvec in vaccines otherwise it will be sitting idle on research desks.
Patent is foundation building block for new idea and approval is first phase. Unless this new idea is manufactured, marketed and implemented, revenues won’t be generated and hence the value
Agreed bidnolid: These are patents: they are basis of future revenues when actual product is manufactured and marketed!
And N4Pharma will need collaboration with big Pharma.If in the eyes of large Phamecutical Company Nuvec is money spinner then it will be taken over. We should live on hope that Nuvec will be not sitting idle on research desks.
Good patent news granted in Europe. ASAP US,China and India is on the list , then company will be ripe for to be taken over to speed up Nuvec of its implementation in delivery of vaccination
Fugazi1: definitely not 250P next week but not 140’s either!
Fugazi1: you are day dreaming , it won’t fall back to mid 140 , you have missed the boat unless market takes a turn in October which is sometimes proves to be market crash month.
Agreed mazik: sit tight and be patient and you never know it will earn us a huge reward. It is bit of a curiosity that why any large Pharma has not grabbed this little company which is so cheap even with paying a hefty premium but will be money spinner.
Bigun2: very good thought , we will be very happy if someone comes with a offer of over a pound! It is a good concept and very practical too but it is amazing, why big Pharma hasn’t come with a offer and to speed up the process and implement Nuvec in vaccination.
Don’t bet on it when MED 3000 gets FDA approval and it won’t yield anything as in Europe of its approval. You needed large Pharma to manufacture and marketing of the product and in the absence of it we are all doomed.
It will be as usual full of empty , hollow and misleading promises, nothing sensational will be in the results apart from drum beating of trial and approval in US.What they have achieved nothing really after excited approval of MED 3000 in Europe.